×
S&P 500   3,825.37 (+1.06%)
DOW   31,097.46 (+1.05%)
QQQ   281.90 (+0.58%)
AAPL   138.26 (+1.13%)
MSFT   258.67 (+0.72%)
META   159.61 (-1.02%)
GOOGL   2,167.30 (-0.55%)
AMZN   109.28 (+2.89%)
TSLA   678.51 (+0.76%)
NVDA   144.93 (-4.39%)
NIO   21.32 (-1.84%)
BABA   115.76 (+1.83%)
AMD   73.52 (-3.86%)
MU   53.46 (-3.29%)
CGC   2.79 (-2.11%)
T   21.33 (+1.77%)
GE   63.62 (-0.08%)
F   11.31 (+1.62%)
DIS   96.08 (+1.78%)
AMC   13.46 (-0.66%)
PFE   52.24 (-0.36%)
PYPL   71.26 (+2.03%)
NFLX   179.12 (+2.43%)
S&P 500   3,825.37 (+1.06%)
DOW   31,097.46 (+1.05%)
QQQ   281.90 (+0.58%)
AAPL   138.26 (+1.13%)
MSFT   258.67 (+0.72%)
META   159.61 (-1.02%)
GOOGL   2,167.30 (-0.55%)
AMZN   109.28 (+2.89%)
TSLA   678.51 (+0.76%)
NVDA   144.93 (-4.39%)
NIO   21.32 (-1.84%)
BABA   115.76 (+1.83%)
AMD   73.52 (-3.86%)
MU   53.46 (-3.29%)
CGC   2.79 (-2.11%)
T   21.33 (+1.77%)
GE   63.62 (-0.08%)
F   11.31 (+1.62%)
DIS   96.08 (+1.78%)
AMC   13.46 (-0.66%)
PFE   52.24 (-0.36%)
PYPL   71.26 (+2.03%)
NFLX   179.12 (+2.43%)
S&P 500   3,825.37 (+1.06%)
DOW   31,097.46 (+1.05%)
QQQ   281.90 (+0.58%)
AAPL   138.26 (+1.13%)
MSFT   258.67 (+0.72%)
META   159.61 (-1.02%)
GOOGL   2,167.30 (-0.55%)
AMZN   109.28 (+2.89%)
TSLA   678.51 (+0.76%)
NVDA   144.93 (-4.39%)
NIO   21.32 (-1.84%)
BABA   115.76 (+1.83%)
AMD   73.52 (-3.86%)
MU   53.46 (-3.29%)
CGC   2.79 (-2.11%)
T   21.33 (+1.77%)
GE   63.62 (-0.08%)
F   11.31 (+1.62%)
DIS   96.08 (+1.78%)
AMC   13.46 (-0.66%)
PFE   52.24 (-0.36%)
PYPL   71.26 (+2.03%)
NFLX   179.12 (+2.43%)
S&P 500   3,825.37 (+1.06%)
DOW   31,097.46 (+1.05%)
QQQ   281.90 (+0.58%)
AAPL   138.26 (+1.13%)
MSFT   258.67 (+0.72%)
META   159.61 (-1.02%)
GOOGL   2,167.30 (-0.55%)
AMZN   109.28 (+2.89%)
TSLA   678.51 (+0.76%)
NVDA   144.93 (-4.39%)
NIO   21.32 (-1.84%)
BABA   115.76 (+1.83%)
AMD   73.52 (-3.86%)
MU   53.46 (-3.29%)
CGC   2.79 (-2.11%)
T   21.33 (+1.77%)
GE   63.62 (-0.08%)
F   11.31 (+1.62%)
DIS   96.08 (+1.78%)
AMC   13.46 (-0.66%)
PFE   52.24 (-0.36%)
PYPL   71.26 (+2.03%)
NFLX   179.12 (+2.43%)
NASDAQ:CLGN

CollPlant Biotechnologies Stock Forecast, Price & News

$8.20
+0.20 (+2.50%)
(As of 07/1/2022 03:04 PM ET)
Add
Compare
Today's Range
$7.95
$8.20
50-Day Range
$8.00
$10.32
52-Week Range
$7.50
$23.00
Volume
251 shs
Average Volume
37,705 shs
Market Capitalization
$90.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

CLGN Stock Forecast (MarketRank)

Overall MarketRank

0.90 out of 5 stars

Medical Sector

1289th out of 1,429 stocks

Surgical Appliances & Supplies Industry

27th out of 30 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
CollPlant Biotechnologies logo

About CollPlant Biotechnologies (NASDAQ:CLGN)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

CLGN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLGN
Employees
52
Year Founded
N/A

Company Calendar

Last Earnings
5/26/2022
Today
7/01/2022
Next Earnings (Estimated)
8/18/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$240 thousand
Net Margins
-1,138.94%
Pretax Margin
-1,138.94%

Debt

Sales & Book Value

Annual Sales
$15.64 million
Book Value
$4.19 per share

Miscellaneous

Free Float
N/A
Market Cap
$90.91 million
Optionable
Not Optionable
Beta
N/A














CollPlant Biotechnologies Frequently Asked Questions

How has CollPlant Biotechnologies' stock performed in 2022?

CollPlant Biotechnologies' stock was trading at $16.36 at the start of the year. Since then, CLGN stock has decreased by 49.9% and is now trading at $8.20.
View the best growth stocks for 2022 here
.

When is CollPlant Biotechnologies' next earnings date?

CollPlant Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our earnings forecast for CollPlant Biotechnologies
.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) released its quarterly earnings data on Thursday, May, 26th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.22. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $2.74 million. CollPlant Biotechnologies had a negative net margin of 1,138.94% and a negative trailing twelve-month return on equity of 29.53%.
View CollPlant Biotechnologies' earnings history
.

Who are CollPlant Biotechnologies' key executives?

CollPlant Biotechnologies' management team includes the following people:
  • Mr. Yehiel Tal, Chief Exec. Officer (Age 70, Pay $970k)
  • Mr. Eran Rotem CPA, Deputy CEO & CFO (Age 54, Pay $692k)
  • Dr. Ilana Belzer, Chief Operations Officer (Age 62, Pay $317k)
  • Prof. Oded Shoseyov, Founder & Chief Scientist (Age 66)
  • Ms. Michal Roytman, VP of Sales & Marketing (Age 37)
  • Ms. Hadas Dreiher Horowitz, VP of HR (Age 45)

What other stocks do shareholders of CollPlant Biotechnologies own?

When did CollPlant Biotechnologies IPO?

(CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

What is CollPlant Biotechnologies' stock symbol?

CollPlant Biotechnologies trades on the NASDAQ under the ticker symbol "CLGN."

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CollPlant Biotechnologies' stock price today?

One share of CLGN stock can currently be purchased for approximately $8.20.

How much money does CollPlant Biotechnologies make?

CollPlant Biotechnologies (NASDAQ:CLGN) has a market capitalization of $90.91 million and generates $15.64 million in revenue each year. The company earns $240 thousand in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does CollPlant Biotechnologies have?

CollPlant Biotechnologies employs 52 workers across the globe.

How can I contact CollPlant Biotechnologies?

CollPlant Biotechnologies' mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The official website for CollPlant Biotechnologies is www.collplant.com. The company can be reached via phone at 972732325600, via email at [email protected], or via fax at 972-73-232-5602.

This page (NASDAQ:CLGN) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.